augmentin antibiotic pret

In a recent study published on the preprint server medRxiv*, researchers evaluate the safety and immunogenicity profiles of a high-dose quadrivalent influenza vaccine and a messenger ribonucleic acid (mRNA)-based coronavirus disease 2019 (COVID-19) vaccine that were administered concomitantly to older adults. The findings demonstrate that co-administration of two vaccines is safe, well-tolerated, and does not cause any immune interference.

Study: Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, seroquel xr sleep dosage open-label study. Image Credit: CROCOTHERY /


The influenza virus is a seasonal respiratory virus that affects all age groups and can cause serious complications in older adults. Influenza infections in older adults aged 65 years and older are associated with excess mortality rates of 3 to 44 per 100,000 individuals. Besides respiratory complications, influenza infections can lead to aggravation of preexisting health conditions, functional disabilities, and cardiovascular complications.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of COVID-19, is another type of respiratory virus that causes severe and often fatal infections in older adults, immunocompromised patients, and those with preexisting health conditions. However, the rapid development and rollout of several different COVID-19 vaccines have made it possible to control the viral spread and prevent disease severity.

Because of the prioritization of the COVID-19 vaccination campaign to control the pandemic, a significant reduction in the influenza vaccination rate has been observed in many countries. This may potentially increase influenza-related morbidity and mortality among older adults. To increase influenza vaccine uptake and reduce the burden on healthcare systems around the world, the World Health Organization (WHO) has recommended co-administration of influenza and COVID-19 vaccines.

In the current study, the scientists have evaluated the safety and immunogenicity profiles of a high-dose quadrivalent influenza vaccine concomitantly administered with the third booster dose of an mRNA-based COVID-19 vaccine mRNA-1273 in older adults aged 65 years and above.

Study design

The current study is an ongoing Phase II, multiple-center, open-level clinical study conducted in six regions throughout the United States. Older adults who had received the second dose of the mRNA-1273 vaccine at least five months prior were selected for the study. The participants were categorized into three groups, with one group receiving both influenza and mRNA-1273 vaccines concomitantly and the other two groups receiving either of the two vaccines.

The safety and tolerability of vaccines and antibodies developed against the respective vaccine antigens were assessed at baseline and at day 22 post-vaccination.

Important observations

A total of 296 older adults aged 65 years and above were enrolled for the current study. Of the participants, 100 were co-administered with both vaccines, 92 received only the influenza vaccine, and 104 received only the mRNA-1273 vaccine.

Safety profile

Injection site pain and erythema were the most commonly reported side effects in each vaccination group. In the co-vaccination group, the most commonly reported systemic reactions were malaise, fatigue, and myalgia.

In the mRNA-1273 vaccination group, the most common systemic reactions were malaise, fatigue, headache, and myalgia. In the influenza vaccination group, only one participant reported fatigue.    

The percentage of participants spontaneously reporting adverse events (unsolicited) was similar in the co-vaccination and mRNA-1273 vaccination groups. However, participants in the influenza vaccination group less frequently reported unsolicited adversities. In this context, the most commonly reported side effects were hypertension, chemical burns to the eyes, and pruritis at the injection site.    

The frequency of reporting unsolicited systemic adversity was highest in the mRNA-1273 vaccination group, followed by the co-vaccination and influenza vaccination groups. This adversity was muscle spasms. Importantly, no serious adversities or death occurred throughout the study period.

Solicited injection site reactions and systemic reactions occurring up to 7 days post-injection (immunogenicity analysis set).


The high-dose quadrivalent influenza vaccine evaluated in the current study contains influenza A/H1N1, A/H3N2, B/Yamagata, and B/Victoria strains. On day 22 post-vaccination, the levels of antibodies against each influenza strain increased significantly compared to the baseline level. The antibody levels were comparable between the co-vaccination and influenza vaccination groups at day 22, indicating similar seroconversion rates between the two groups for each viral strain of the vaccine.

The levels of immunoglobulin G (IgG)-specific anti-SARS-CoV-2 spike binding antibodies increased significantly at day 22 post-vaccination compared to that at baseline. Notably, these antibody levels were comparable between the co-vaccination and mRNA-1273 only vaccination groups, indicating similar seroconversion rates.

Study significance

The current study reveals that the influenza vaccine and mRNA-1273 vaccine can be co-administered in older adults without causing any severe side effects and immune interference. This can help to improve current influenza vaccination rates, shorten the vaccination period, and reduce the number of visits to healthcare providers.

*Important notice

medRxiv publishes preliminary scientific reports that are not peer-reviewed and, therefore, should not be regarded as conclusive, guide clinical practice/health-related behavior, or treated as established information

Journal reference:
  • Izikson, R., Brune, D., Bolduc, J., et al. (2021). Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults ≥ 65 years of age: a Phase II, open-label study. medRxiv.


Posted in: Men's Health News | Medical Research News | Medical Condition News | Women's Health News | Disease/Infection News

Tags: Antibodies, Antibody, Coronavirus, Coronavirus Disease COVID-19, Erythema, Fatigue, Frequency, H1N1, H3N2, Headache, Healthcare, Immunoglobulin, Influenza, Mortality, Muscle, Pain, Pandemic, Pathogen, Pruritis, Respiratory, Respiratory Virus, Ribonucleic Acid, SARS, SARS-CoV-2, Severe Acute Respiratory, Severe Acute Respiratory Syndrome, Syndrome, Vaccine, Virus

Comments (0)

Written by

Dr. Sanchari Sinha Dutta

Dr. Sanchari Sinha Dutta is a science communicator who believes in spreading the power of science in every corner of the world. She has a Bachelor of Science (B.Sc.) degree and a Master's of Science (M.Sc.) in biology and human physiology. Following her Master's degree, Sanchari went on to study a Ph.D. in human physiology. She has authored more than 10 original research articles, all of which have been published in world renowned international journals.

Source: Read Full Article